AARTIPHARM / NSE / Biotechnology & Drugs
Aarti Pharmalabs
1Y Price Trend
Key Information
Recommendations
Target High971.5
Target Low583.85
Target Mean0
Target Median0
Risk Metrics
Overall RiskBalanced risk
Board Risk43.39
Key Analysis
Overall score, performance score, return rating, defensive, aggressive, and balanced views.
Download appProjection Analytics
Best-case, base-case, worst-case, and dynamic AI projection views.
Download appLatest stock news
Aarti Pharmalabs Yearly results, Financial Summary The Economic Times
Aarti Pharmalabs Ltd is Rated Sell Markets Mojo
Buy, sell or hold: Hitachi Energy, Union Bank, Aarti Pharmalabs, Coal India, Petronet, Balaji Amines — Ask Profit MSN
Aarti Pharmalabs targets 15-18% revenue and EBITDA growth over 3-4 years scanx.trade
Aarti Pharmalabs Insider Ups Holding During Year simplywall.st
Aarti Pharmalabs Ltd (BOM:543748) Q4 2026 Earnings Call Highlights: Revenue Growth Amidst ... By GuruFocus Investing.com Canada
Aarti Pharmalabs uploads Q4FY26 earnings call recording scanx.trade
Aarti Pharmalabs Q4 Results: Shares slide 6% as forex loss, one-offs impact earnings performance CNBC TV18
© SharekeyX | Rusaka Technologies 2024-2026

